In support of its functioning as a tumor suppressor, TFPI-2 is epigenetically silenced in aggressive cancers including, among others, colorectal cancer or CRC [48, 94], glioma [43], NSCLC [44], pancreatic cancer or PC [49], BC [46], melanoma [47], HCC [50], and oral squamous cell carcinoma (OSCC) [95]. Here, TFPI2 is linked to hepatocellular carcinoma.